Kaisa Cui
Overview
Explore the profile of Kaisa Cui including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
664
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wan Q, Wu X, Zhou J, Wu W, Cao Y, Sun C, et al.
Adv Sci (Weinh)
. 2025 Mar;
:e2416231.
PMID: 40047299
Less-aggressive lower-grade gliomas (LGGs) frequently transform into glioblastoma (GBM). Most previous studies of gliomas have not focused on LGG-original high-risk subpopulations, which may be one of the most critical hallmarks...
2.
Zhang Q, Cui K, Kong Y, Yu J, Luo Z, Yang X, et al.
Cell Rep
. 2025 Feb;
44(3):115327.
PMID: 39977268
c-Myc (Myc)-driven cancers exhibit aggressive phenotypes and therapeutic resistance. Here, integrating CRISPR-Cas9 screening, we identify dihydroorotate dehydrogenase (DHODH) as a promising target in Myc-driven cancer. Mechanistically, DHODH interacts with Myc...
3.
Cui K, Wang K, Huang Z
J Exp Clin Cancer Res
. 2024 Nov;
43(1):315.
PMID: 39614322
Ferroptosis is a type of regulated cell death characterized by its non-apoptotic, iron-dependent and oxidative nature. Since its discovery in 2012, extensive research has demonstrated its pivotal roles in tumorigenesis,...
4.
Wang Y, Cao Y, Chen Y, Cheng H, Liu Z, Wang M, et al.
Med Oncol
. 2024 Mar;
41(5):100.
PMID: 38538804
Colorectal cancer (CRC) ranks as the third most prevalent cancer type globally. Nevertheless, the fundamental mechanisms driving CRC progression remain ambiguous, and the prognosis for the majority of patients diagnosed...
5.
Teng P, Cui K, Yao S, Fei B, Ling F, Li C, et al.
Cell Death Differ
. 2023 Nov;
31(1):65-77.
PMID: 38007551
Mitochondrial malic enzyme 2 (ME2), which catalyzes the conversion of malate to pyruvate, is frequently upregulated during tumorigenesis and is a potential target for cancer therapy. However, the regulatory mechanism...
6.
Gong L, Tian L, Cui K, Chen Y, Liu B, Li D, et al.
J Control Release
. 2023 Nov;
364:672-686.
PMID: 37967724
Small extracellular vesicles (sEVs) have shown excellent prospects as drug delivery systems for cancer therapy. However, the inherent non-targeting and short blood circulation characteristics severely restrict their practical applications as...
7.
Li C, Teng P, Sun S, Cui K, Yao S, Fei B, et al.
J Biol Chem
. 2023 Jul;
299(9):105090.
PMID: 37507016
Folate-mediated one-carbon metabolism (FOCM) is crucial in sustaining rapid proliferation and survival of cancer cells. The folate cycle depends on a series of key cellular enzymes, including aldehyde dehydrogenase 1...
8.
Zhang Y, Cui K, Yang Y, Liu B, Zhu M, Chen H, et al.
J Hepatocell Carcinoma
. 2023 Jul;
10:1051-1067.
PMID: 37449280
Introduction: Immune checkpoint (IC) inhibitor-related immunotherapies have attracted considerable attention in hepatocellular carcinoma (HCC). High IC expression and high tumor infiltrating lymphocyte levels are the current indicators of sensitivity to...
9.
Zhang Q, Cui K, Yang X, He Q, Yu J, Yang L, et al.
Clin Transl Med
. 2023 Jan;
13(1):e1164.
PMID: 36629054
Background: Metabolic reprogramming is a hallmark of cancer. Metabolic rate-limiting enzymes and oncogenic c-Myc (Myc) play critical roles in metabolic reprogramming to affect tumourigenesis. However, a systematic assessment of metabolic...
10.
Wang X, Cheng H, Zhao J, Li J, Chen Y, Cui K, et al.
Mol Cancer
. 2022 Nov;
21(1):210.
PMID: 36376892
Background: Long noncoding RNAs (lncRNAs) have driven research focused on their effects as oncogenes or tumor suppressors involved in carcinogenesis. However, the functions and mechanisms of most lncRNAs in colorectal...